Top Banner
Evading Immune Responses and Tumor Immunology Amy Lovett-Racke, PhD Associate Professor Department of Microbial Infection and Immunity
26

Evading Immune Responses and Tumor Immunology Amy Lovett-Racke, PhD Associate Professor Department of Microbial Infection and Immunity.

Dec 16, 2015

Download

Documents

Darrell Berry
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Evading Immune Responses and Tumor Immunology Amy Lovett-Racke, PhD Associate Professor Department of Microbial Infection and Immunity.

Evading Immune Responses and Tumor Immunology

Amy Lovett-Racke, PhDAssociate ProfessorDepartment of Microbial Infection and Immunity

Page 2: Evading Immune Responses and Tumor Immunology Amy Lovett-Racke, PhD Associate Professor Department of Microbial Infection and Immunity.

Copyright © Garland Science 2009

Peter Parham

The Immune System

• Third Edition• Chapter 16

Cancer and Its Interactions with the Immune System

Page 3: Evading Immune Responses and Tumor Immunology Amy Lovett-Racke, PhD Associate Professor Department of Microbial Infection and Immunity.

Learning Objectives

Know the difference in tumor-specific and tumor-associated antigens.

Understand the evidence that the immune system limits the development of cancer.

Compare and contrast the role of NK cells and CD8 T cells in the eradication of tumor cells.

Understand the mechanisms of immune evasion by cancer cells.

Page 4: Evading Immune Responses and Tumor Immunology Amy Lovett-Racke, PhD Associate Professor Department of Microbial Infection and Immunity.

mutations – alterations in DNAtumor (swelling) = neoplasm (new growth)oncology – branch of medicine dealing with tumors

Encapsulated, localized and limited in size.

Can continue to grow by breaking through basal laminae and invading adjacent tissue.

Benign versus Malignant Tumors

Page 5: Evading Immune Responses and Tumor Immunology Amy Lovett-Racke, PhD Associate Professor Department of Microbial Infection and Immunity.

Carcinoma – cancers of epithelial cells; Sarcoma – cancers of other cell types.

Cancers of the Immune SystemLeukemia – cancer of circulating immune cellsLymphoma – solid lymphoid tumorsMyeloma – tumor of plasma cells in bone marrow

Common Tissues of Cancer Origin in the USA

Page 6: Evading Immune Responses and Tumor Immunology Amy Lovett-Racke, PhD Associate Professor Department of Microbial Infection and Immunity.

Malignant transformation – when a cell has mutated such that it has become cancerous.

Proto-oncogens – genes that normally contribute positively to the initiation and execution of cell division.

Oncogenes – mutant forms of proto-oncogenes that contribute to malignant transformation.

Tumor suppressor genes – encode proteins that prevent the unwanted proliferation of mutant cells.

Multiple Mutations are Required for Cancer Development

Page 7: Evading Immune Responses and Tumor Immunology Amy Lovett-Racke, PhD Associate Professor Department of Microbial Infection and Immunity.

Mutagen – chemical or physical agent that damage DNA in such a way as to cause an increased rate of mutations.

Carcinogen – mutagens that are known to increase the risk of cancer.

Oncogenic virus – viruses that have the potential to transform cells and promote tumor formation.

Some Cancers are Associated with Viruses

Page 8: Evading Immune Responses and Tumor Immunology Amy Lovett-Racke, PhD Associate Professor Department of Microbial Infection and Immunity.

Immunosurveillence or Cancer Immunosurveillence – the ability of the immune system to detect and eliminate tumors at an early stage.

Common Characteristics of Cancer Cells

Page 9: Evading Immune Responses and Tumor Immunology Amy Lovett-Racke, PhD Associate Professor Department of Microbial Infection and Immunity.

Rate of Growth of Cancer

Page 10: Evading Immune Responses and Tumor Immunology Amy Lovett-Racke, PhD Associate Professor Department of Microbial Infection and Immunity.

Alloantigens – antigen that differs between members of the same species, such as HLA molecules. Alloantigens are recognized as foreign and elicit adaptive immune responses to eradicate the antigen.

MHC is Critical in Immune Recognition of Tumors

Page 11: Evading Immune Responses and Tumor Immunology Amy Lovett-Racke, PhD Associate Professor Department of Microbial Infection and Immunity.

Tumor-specific antigen – antigen expressed on tumor cells but not on

normal cells.

Tumor-associated antigen – antigen expressed on tumor cells but also found on normal cells, often in smaller amounts.

Tumor-Specific Antigens

Page 12: Evading Immune Responses and Tumor Immunology Amy Lovett-Racke, PhD Associate Professor Department of Microbial Infection and Immunity.

Antigens Commonly Mutated in Cancer

Page 13: Evading Immune Responses and Tumor Immunology Amy Lovett-Racke, PhD Associate Professor Department of Microbial Infection and Immunity.

Generation of Novel Tumor Antigens

Page 14: Evading Immune Responses and Tumor Immunology Amy Lovett-Racke, PhD Associate Professor Department of Microbial Infection and Immunity.

NK cell gd T cell

MICNKG2D

Evasion of the Immune Response by Tumors

Page 15: Evading Immune Responses and Tumor Immunology Amy Lovett-Racke, PhD Associate Professor Department of Microbial Infection and Immunity.

CD8

cancer cell

CD8 T cell

tumor antigen

Cancer Cell

Evasion of the Immune Response by Tumors

Page 16: Evading Immune Responses and Tumor Immunology Amy Lovett-Racke, PhD Associate Professor Department of Microbial Infection and Immunity.

Tumor antigen

Tumor antigen

If a tumor antigen is presented by an activated macrophage or mature dendritic cell, B7 (CD80/86) will be present on the antigen presenting cells (APCs) and the tumor-specific CD8 T cell will be able to become activated and kill tumor cells.

However, APCs are often not activated by tumors and therefore, the APCs remain in an immature or inactivated state. These APCs will not express the costimulator molecule B7 (CD80/86) and therefore, T cells specific for the tumor antigens will not become activated. They will become anergic or unresponsive, allowing the tumor to go undetected by CD8 T cells.

Evasion of the Immune Response by Tumors

Page 17: Evading Immune Responses and Tumor Immunology Amy Lovett-Racke, PhD Associate Professor Department of Microbial Infection and Immunity.

Evasion of the Immune Response by Tumors

Page 18: Evading Immune Responses and Tumor Immunology Amy Lovett-Racke, PhD Associate Professor Department of Microbial Infection and Immunity.

Vaccination with Tumor Antigens

Page 19: Evading Immune Responses and Tumor Immunology Amy Lovett-Racke, PhD Associate Professor Department of Microbial Infection and Immunity.

monoclonal antibody – antibodies produced by a single B cell clone and thus are all identical in structure and antigen specificity.

Monoclonal Antibodies Detect and Treat Cancer

Page 20: Evading Immune Responses and Tumor Immunology Amy Lovett-Racke, PhD Associate Professor Department of Microbial Infection and Immunity.

Monoclonal Antibodies Detect and Treat Cancer

Page 21: Evading Immune Responses and Tumor Immunology Amy Lovett-Racke, PhD Associate Professor Department of Microbial Infection and Immunity.

Monoclonal Antibodies Detect and Treat Cancer

Page 22: Evading Immune Responses and Tumor Immunology Amy Lovett-Racke, PhD Associate Professor Department of Microbial Infection and Immunity.

Monoclonal Antibodies Detect and Treat Cancer

Page 23: Evading Immune Responses and Tumor Immunology Amy Lovett-Racke, PhD Associate Professor Department of Microbial Infection and Immunity.

Monoclonal Antibodies Detect and Treat Cancer

Page 24: Evading Immune Responses and Tumor Immunology Amy Lovett-Racke, PhD Associate Professor Department of Microbial Infection and Immunity.

Difference between tumor-specific and tumor associated antigens.

Evidence that the immune response limits the development of cancers.

Primary immune mechanisms to recognize and kill tumor cells• CD8 T cells• NK cells

Mechanisms of immune evasions by cancers.• Cleavage of Mic proteins on tumor cells and internationalization of NKG2D by NK cells

and γδ T cells.• Down regulation of MHC class I to evade CD8 T cells.• Down regulation of tumor antigens so they are undetectable by CD8 T cells.• Lack of costimulatory molecules on antigen presenting cells, resulting in anergic T cells.• Recruitment of Tregs to the tumor environment, and production of cytokines (TGFβ and

IL-10) to suppress antigen-specific T cells in the tumor environment.

Things You Should Know

Page 25: Evading Immune Responses and Tumor Immunology Amy Lovett-Racke, PhD Associate Professor Department of Microbial Infection and Immunity.

Evading Immune Responses Quiz

Page 26: Evading Immune Responses and Tumor Immunology Amy Lovett-Racke, PhD Associate Professor Department of Microbial Infection and Immunity.

[email protected]

Thank you for completing this module